Recommended NZ | Guide to Money | Gimme: Competitions - Giveaways

Munchkin U.S. FDA process on hold - Synlait Milk

Fuseworks Media
Fuseworks Media

The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass Fed infant formula in the U.S. has been put on hold.

Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S.

"Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed is sold the relationship continues with business as usual," says Synlait CEO, Leon Clement.

The development will not have a material impact on Synlait’s forecast infant formula volumes.

All articles and comments on have been submitted by our community of users. Please notify us if you believe an item on this site breaches our community guidelines.